Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role
Open Access
- 11 October 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 120 (15), 3030-3038
- https://doi.org/10.1182/blood-2012-05-427799
Abstract
Tumor cells can induce certain cytokines and soluble receptors that have a suppressive effect on the immune system. In this study, we showed that an extracellular portion of a membrane-bound ligand of CD40 (soluble CD40 ligand; sCD40L) was significantly elevated in the serum of cancer patients compared with healthy donors. In addition, PBMCs from cancer patients had a relatively larger population of myeloid-derived suppressor cells (MDSCs), defined as CD33+HLA-DR− cells, and these cells expressed higher levels of CD40. T-cell proliferation and IFN-γ production decreased when stimulated T cells were cocultured with an increased amount of autologous MDSCs. The addition of recombinant monomeric sCD40L enriched MDSCs and had an additive inhibitory effect on T-cell proliferation. PBMCs cultured in vitro with sCD40L also showed an expansion of regulatory T cells (CD4+CD25highFoxp3+), as well as induction of cytokines, such as IL-10 and IL-6. Moreover, sCD40L-induced enrichment of programmed death-1–expressing T cells was greater in cancer patients than in healthy donors. Preexisting sCD40L also inhibited IL-12 production from monocytes on activation. These data suggest that the higher levels of sCD40L seen in cancer patients may have an immunosuppressive effect. These studies were registered at www.clinicaltrials.gov as NCT00060528, NCT00019695, NCT00179309, NCT00514072, NCT00081848, and NCT00436956.Keywords
This publication has 39 references indexed in Scilit:
- Myeloid derived suppressor cells in human diseasesInternational Immunopharmacology, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapyCancer, 2010
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in CancerCancer Research, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Giving blood: a new role for CD40 in tumorigenesisThe Journal of Experimental Medicine, 2006
- Triggering CD40 on endothelial cells contributes to tumor growthThe Journal of Experimental Medicine, 2006
- Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery diseaseAmerican Heart Journal, 2006
- Human Native Soluble CD40L Is a Biologically Active Trimer, Processed Inside MicrosomesPublished by Elsevier BV ,1996